<DOC>
	<DOCNO>NCT02991872</DOCNO>
	<brief_summary>The purpose study evaluate long-term persistence immune response approximately 5 year simulated rabies post-exposure prophylaxis provide 2012 accord Essen ( 1-1-1-1-1 ) Zagreb ( 2-1-1 ) intramuscular ( IM ) regimens subset subject participate parent study ( V49_24 [ NCT01680016 ] ) age ≥6 ≤17 year time enrollment . This study aim respond post-marketing commitment China Food Drug Administration ( CFDA ) request time renewal purify chicken-embryo cell rabies vaccine license China , grant August 2015 .</brief_summary>
	<brief_title>A Study Evaluate Persistence Immune Responses After Post-exposure Prophylaxis Rabipur® ( Purified Chicken-embryo Cell Rabies Vaccine ) Chinese Children</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Subjects age ≥ 6 ≤17 time enrollment parent study sign informed consent prior extension study entry , receive full PEP parent study accord either Zagreb Essen intramuscular regimen . 2 . Subjects whose parent ( ) /legal guardian ( ) voluntarily give write informed consent/assent extension study nature study explain accord local regulatory requirement , prior study entry . 3 . Individuals comply study procedure . Prior extension study entry , subject must : 1 . Documented medical history exposure rabies rabies prophylaxis completion parent study ( V49_24 [ NCT01680016 ] ) study start . 2 . Participated parent study ( V49_24 [ NCT01680016 ] ) receive full PEP vaccination course ( receive window ) follow assignment either Zagreb Essen regimen parent study . 3 . Progressive , unstable uncontrolled clinical condition . 4 . Clinical condition represent contraindication blood draw . 5 . Abnormal function immune system result : 1 . Clinical condition . 2 . Systemic administration corticosteroid 14 consecutive day within 90 day prior inform consent age group . 3 . Administration antineoplastic immunomodulating agent radiotherapy within 90 day prior inform consent age group . 6 . Received immunoglobulin blood product within 180 day prior inform consent age group . 7 . Study personnel immediate family household member . 8 . Any clinical condition , opinion investigator , might pose additional risk subject due participation study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Persistence</keyword>
	<keyword>Purified chicken-embryo cell rabies vaccine</keyword>
	<keyword>Rabies Virus Neutralizing Antibody ( RVNA )</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Post-Exposure Prophylaxis ( PEP )</keyword>
	<keyword>Rabipur</keyword>
</DOC>